Premium
Statin‐associated myopathy and its exacerbation with exercise
Author(s) -
Meador Benjamin M.,
Huey Kimberly A.
Publication year - 2010
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21817
Subject(s) - myopathy , statin , medicine , rhabdomyolysis , myalgia , exacerbation , creatine kinase , skeletal muscle , muscle weakness , pharmacology , bioinformatics , endocrinology , biology
3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are a common and effective treatment for hypercholesterolemia, with a low overall rate of side‐effects. The most common complication is some degree of skeletal muscle myopathy, ranging from painless serum creatine kinase elevations to rhabdomyolysis. Unfortunately, the likelihood and/or severity of complications increases with the combination of statin treatment and physical activity. The specific pathways that mediate statin‐associated myopathy are unclear, and research directly addressing the exacerbation with exercise is limited. Potential mechanisms include the induction of skeletal muscle fiber apoptosis, alterations in ubiquitin–proteasome pathway activity, mitochondrial dysfunction, and terpenoid depletion. In this review we provide an overview of research that specifically addresses the combination of statin‐associated myopathy and physical activity and highlight some deficiencies in the available literature, as well as future directions for this important subset of statin‐associated myopathy. Muscle Nerve, 2010